Featured Videos on LONHALA MAGNAIR for COPD Treatment

Featured Videos on LONHALA MAGNAIR for COPD Treatment

Watch these videos to hear what these experts have to say about LONHALA MAGNAIR

See a panel of experts discuss how nebulization is going places as they review key device features as well as clinical efficacy and safety data for LONHALA MAGNAIR. Then, watch a video about the evolution of nebulizer technology leading up to MAGNAIR.

MAGNAIR device is a portable, battery-operated nebulizer.
 

 

Advances in
Nebulization

Watch these videos for details on the MAGNAIR device features

Watch these videos for details on the MAGNAIR device features

Take an up-close and detailed look at LONHALA MAGNAIR and its key device features. Then watch how your patients will set up and administer LONHALA MAGNAIR.

MAGNAIR:
A Closer Look
How to Use
LONHALA MAGNAIR

Can't see the video or want more detailed information? Read or download the Manufacturer's Instructions for Use, Quick Reference Guide, or Patient Information.

COPD=chronic obstructive pulmonary disease.

Looking for more?

See features of the twice-daily LONHALA MAGNAIR for your COPD patients

Watch more videos

 

Important Safety Information & Indication

Important Safety Information
 

LONHALA MAGNAIR is contraindicated in patients with a hypersensitivity to glycopyrrolate or to any of the ingredients.

LONHALA MAGNAIR should not be initiated in patients with acutely deteriorating or potentially life-threatening episodes of COPD or used as rescue therapy for acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

As with other inhaled medicines, LONHALA MAGNAIR can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with LONHALA MAGNAIR, it should be treated immediately with an inhaled, short-acting bronchodilator; LONHALA MAGNAIR should be discontinued immediately and alternative therapy instituted.

Immediate hypersensitivity reactions have been reported with LONHALA MAGNAIR. If signs occur, discontinue LONHALA MAGNAIR immediately and institute alternative therapy.

LONHALA MAGNAIR should be used with caution in patients with narrow-angle glaucoma and in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema) and of urinary retention (e.g., difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Patients should be instructed to consult a physician immediately should any of these signs or symptoms develop.

The most common adverse events reported in ≥2% of patients taking LONHALA MAGNAIR, and occurring more frequently than in patients taking placebo, were dyspnea (4.9% vs 3.0%) and urinary tract infection (2.1% vs 1.4%).

LONHALA solution is for oral inhalation only and should not be injected or swallowed. LONHALA vials should only be administered with MAGNAIR.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For additional information, please see full Prescribing Information and Patient Information for LONHALA MAGNAIR at www.sunovionprofile.com/lonhala-magnair.

Indication
 

LONHALA® MAGNAIR® (glycopyrrolate) is an anticholinergic indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.